
Stock recommendations for 30 March from MarketSmith India
Why it’s recommended: Strong presence in the US generics market, diversified product portfolio, robust R&D capabilities, improving margins and cost control, growth in the speciality and injectables segment, healthy balance sheet, consistent revenue growth, backward integration benefits, expanding global footprint, and regulatory compliance improvements.Key metrics: P/E: 21.34 | 52-week high: ₹1,330.00 | Volume: ₹245.07 croreTechnical analysis: Cup-base breakoutRisk factors: The USFDA regulatory risks, pricing pressure in generics, high dependence on the US market, currency fluctuation impact, litigation and compliance risks, API business volatility, intense industry competition, delay in product approvals, margin pressure risk, and geopolitical and export risks.Buy: ₹1,300-1,320Target price: ₹1,450 in two to three monthsStop loss: ₹1,240Why it’s recommended: Government-owned status with strong backing, integrated power and mining business, consistent profitability track record, expansion into renewable energy, large capex growth plans, stable cash flows due to utility nature, diversification into EV and storage, improving revenue growth trend, decent margins over cycles, and strategic importance in the energy sector.Key metrics: P/E:13.46 | 52-week high: ₹292.20 | Volume: ₹67.59 croreTechnical analysis: Reclaimed its 21-DMARisk factors: High capex leading to cash flow pressure, dependence on lignite and thermal power, regulatory and environmental risks, long gestation project risks, possibility of increased debt, power tariff regulation risk, execution risk in expansion plans, uncertainty in renewable transition, commodity and fuel price risk, and PSU-related governance constraints.Buy at: ₹268-271Target price: ₹298 in
. Read on livemint.com